close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Russell 2000 BuyWrite ETF (NY:IWMW)

38.55 +0.23 (+0.61%)
Streaming Delayed Price Updated: 2:55 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Russell 2000 BuyWrite ETF

< Previous 1 2 3 4 5 Next >
News headline image
LUMN Stock Climbs 5% Pre-Market – What’s The Anthropic Connection? ↗
The company outlined several multi-year financial goals, including expansion of EBITDA margins to the mid-30% range by 2030. 
Via Stocktwits
Topics Artificial Intelligence
IONQ Stock Tumbles 10% As Wolfpack Reveals Short Position ↗
Via Stocktwits
News headline image
Why Is TeraWulf Stock Rallying More Than 10% After Hours? ↗
With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites. 
Via Stocktwits
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs ↗
Via Stocktwits
PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy ↗
Via Stocktwits
Peloton Reportedly Lays Off 11% Workforce ↗
Via Stocktwits
RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction ↗
Via Stocktwits
Bumble Chief Product Officer Reportedly Exits Amid Dating Platform’s ‘Return To Growth’ Efforts ↗
Via Stocktwits
VITL Shares Slip 6% On Health Concerns Around Eggs: Analyst Dismisses ‘Misleading’ Information, Reiterates ‘Buy’ Rating ↗
Via Stocktwits
USA Rare Earth Rallies More than 11% - What’s Driving The Optimism? ↗
Via Stocktwits
News headline image
KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism? ↗
The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for its new development candidate KRRO-121. 
Via Stocktwits
News headline image
Bloom Energy Shares Surge – Why Are Analysts Initiating Coverage On The Stock? ↗
Brokerages like Barclays and China Renaissance initiated coverage on Bloom Energy. 
Via Stocktwits
News headline image
LUNR Shares Edge Up 3% After Hours — What's Intuitive’s Role In NASA’s Artemis Program? ↗
Intuitive is now part of 34 global volunteers chosen by the agency to track Artemis II. 
Via Stocktwits
News headline image
IOVA Shares Jump 8% — What’s Retail Expecting? ↗
Iovance is a commercial stage immuno-oncology company seeking to deliver tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. 
Via Stocktwits
News headline image
Sable Offshore Plunged 14% Today – What Is The Feud With California State? ↗
California Attorney General Rob Bonta on Friday filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders of allowing... 
Via Stocktwits
Topics Government Lawsuit
IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing ↗
Via Stocktwits
IBRX Stock Continues Rally — What’s Driving The Optimism Today? ↗
Via Stocktwits
Bakkt Stock Rallies Nearly 20% - What’s Behind The Move? ↗
Via Stocktwits
News headline image
Why This Small-Cap Penny Stock Is Rallying Today – Traders Expect Stock Price To Double ↗
United States Antimony earlier in the week announced the closing of a property acquisition of a critical minerals flotation facility. 
Via Stocktwits
News headline image
ALT Stock Rallies 4% — What Does Retail Think? ↗
Earlier this month, Altimmune said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide for the treatment of patients with metabolic... 
Via Stocktwits
News headline image
BigBear.ai Shares Tumble 8% Ahead Of Crucial Shareholder Vote Deadline On Increasing Authorized Shares ↗
The company wants its investors to approve an amendment for increasing its authorized common shares from 500 million to 1 billion shares. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? ↗
The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 
Via Stocktwits
SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? ↗
Via Stocktwits
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March ↗
Via Stocktwits
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 ↗
Via Stocktwits
News headline image
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 ↗
The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗
Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S. 
Via Stocktwits
News headline image
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? ↗
The company said it made significant commercial progress in 2025, generating approximately $378 million in product revenue. 
Via Stocktwits
News headline image
ELVN Stock Shot Up 60% Today – What’s Driving The Rally? ↗
The company reported positive initial data from its ongoing Phase 1b clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia. 
Via Stocktwits
News headline image
Joby Inks $61.5 Million Deal To Acquire Another Ready-To-Use Facility In Ohio As It Eyes Doubling eVTOL Production ↗
The new facility spans more than 700,000 feet and is ready for immediate use, the California-based company said. 
Via Stocktwits
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today